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1. INTRODUCTION {#gcc22679-sec-0001}
===============

Mycosis fungoides (MF) is the most common type of cutaneous T‐cell lymphoma (CTCL), a heterogeneous group of neoplasms derived from malignant skin‐homing T cells. MF typically evolves from erythematous cutaneous patches and/or plaques to tumors. Patients with tumor‐stage MF have a 10‐year survival of 42%, which shows the need of a better understanding of the disease and more effective treatments.[1](#gcc22679-bib-0001){ref-type="ref"}

Inactivation of tumor suppressors *CDKN2A* and *CDKN2B* are established genetic alterations in MF, whereas mutations in *FAS* have been reported in subsets of patients.[2](#gcc22679-bib-0002){ref-type="ref"}, [3](#gcc22679-bib-0003){ref-type="ref"}, [4](#gcc22679-bib-0004){ref-type="ref"} In recent years, the copy number alteration (CNA), micro‐RNA (miRNA), and mutational profiles of MF have been investigated using genome‐wide array technologies and next generation sequencing (NGS).

Common CNAs include losses within chromosomes 1, 5, 9, and 13, and gains within chromosomes 7 and 17.[5](#gcc22679-bib-0005){ref-type="ref"} Highlights of miRNA expression are up‐regulation of oncomirs miR‐93 and miR‐155.[6](#gcc22679-bib-0006){ref-type="ref"} Gain‐of‐function single nucleotide variants (SNVs) found in solitary or few cases include *JAK3* (p.A573V), *MAPK1* (p.E322K), *STAT3* (p.Y640F), *PLCG1* (p.S345F, p.S520F), and *TNFRSF1B* (p.T377I).[7](#gcc22679-bib-0007){ref-type="ref"}, [8](#gcc22679-bib-0008){ref-type="ref"}, [9](#gcc22679-bib-0009){ref-type="ref"}, [10](#gcc22679-bib-0010){ref-type="ref"}, [11](#gcc22679-bib-0011){ref-type="ref"}

Even though this body of information has shed some light on the pathogenetics of MF, driver genetic alterations remain unknown. Particularly, the low recurrence of pathogenic small‐scale mutations (ie, SNVs, indels) manifests the need of research on additional facets of MF genetics.

To date, no study has provided insight into the landscape of genomic rearrangements underlying MF. Consequently, we performed an integrated whole‐genome sequencing (WGS)/RNA‐sequencing (RNA‐seq) analysis of tumor‐stage MF to investigate structural aberrations at base‐level resolution.

Our results reveal numerous rearrangements associated with CNAs, and affecting genes involved in signal transduction and transcriptional regulation. Moreover, we identify two recurrently deleted tumor suppressors, *HNRNPK* and *SOCS1*, that are novel to MF genetics. These findings broaden our understanding of MF and provide new potential targets for treatment.

2. MATERIALS AND METHODS {#gcc22679-sec-0002}
========================

2.1. Patient selection {#gcc22679-sec-0003}
----------------------

Frozen skin biopsies from nine patients with tumor‐stage MF (IIB‐IVA2, Supporting Information Table [1](#gcc22679-supitem-0002){ref-type="supplementary-material"}) were selected for this study. Diagnosis was based on the criteria of the WHO‐EORTC classification for primary cutaneous lymphomas[1](#gcc22679-bib-0001){ref-type="ref"} and confirmed by an expert panel of dermatologist and pathologists. We subjected eight tumor biopsies to WGS and RNA‐seq, and one biopsy to WGS only. Eighteen additional frozen tumor biopsies (IIB‐IVA2, Supporting Information Table [1](#gcc22679-supitem-0002){ref-type="supplementary-material"}) were used as a validation cohort. Whenever available, formalin‐fixed paraffin‐embedded (FFPE) tumor biopsies were used for validation experiments (sequenced and extension cohorts) by fluorescence *in situ* hybridization (FISH). Frozen and FFPE tumor biopsies contained ≥70% malignant T cells. Patient material was approved by the Leiden University Medical Center institutional review board and informed consent was obtained in accordance with the declaration of Helsinki.

2.2. DNA and RNA isolation {#gcc22679-sec-0004}
--------------------------

Genomic DNA was isolated using Genomic‐tip 20/G kit (Qiagen) following the manufacturer\'s protocol. DNA purity (A260/280 and A260/230 ratios) was evaluated using a Nanodrop 1000 system (Nanodrop Technologies, Wilmington, CA). DNA integrity was verified by gel electrophoresis (0.7% agarose, ethidium bromide). Total RNA was isolated using RNeasy mini kit (Qiagen). RNA integrity was verified with an Agilent 2100 Bioanalyzer.

2.3. Sequencing {#gcc22679-sec-0005}
---------------

DNA and RNA were sequenced by the Beijing Genomics Institute (BGI). For whole‐genome sequencing, DNA libraries were prepared using TruSeq Nano DNA HT sample prep kit (Illumina), which involves DNA fragmentation by Covaris sonication, end‐repair, A‐tailing, adapter ligation, and fragment enrichment. Purified DNA fragments were subjected to paired‐end sequencing (2 × 150 bp) on the Illumina HiSeq X‐Ten platform. For RNA sequencing, total RNA was depleted from rRNA using Ribo‐Zero Magnetic kit (Epicentre Biotechnologies, Madison, WI), fragmented, and followed by first‐strand cDNA synthesis, second‐strand cDNA synthesis (with dUTP instead of dTTP), end repair, A‐tailing, adapter ligation, uracil‐N‐glycosylase treatment, and cDNA library enrichment. Purified cDNA libraries were subjected to paired‐end sequencing (2 × 100 bp) on the Illumina HiSeq 4000 platform. All NGS data have been deposited in the European Genome‐Phenome Archive (EGA) under study number EGAS00001002860.

2.4. Sequence data processing {#gcc22679-sec-0006}
-----------------------------

For whole‐genome sequencing, raw reads were processed using FastQC (v0.11.2), SeqTK (v1.0‐r63), Cutadapt, and Sickle (v1.33). Clean reads were aligned to the human reference genome Hg19 using BWA‐mem (v0.7.10) (Supporting Information Table [2](#gcc22679-supitem-0002){ref-type="supplementary-material"}). For RNA sequencing, raw reads were processed with FastQC (v0.10.1), Cutadapt (v1.5), and Sickle (v1.33). Clean reads were aligned to human reference genome Hg19 using GSNAP (release December 23, 2014). SAM alignments were compressed and indexed with Picard (v1.120), and fragment counts were obtained with HTseq (v0.6.1p1) using UCSC RefSeq annotations (downloaded July 1, 2015).

2.5. Discovery of DNA rearrangements and fusion transcripts {#gcc22679-sec-0007}
-----------------------------------------------------------

Genome structural variation (SV) analysis was performed using a set of tools that included Pindel (v0.2.5b8), CleverSV (v2.0rc3), Breakdancer‐max (v1.4.4), and Delly (v0.6.7). Postprocessing of the SV calls included sorting and merging of the calls using a local script and pySVTools (v0.1.3). Each of the structural variant callers were used with default settings and following best practices. SV calls were manually verified and curated using the Integrative Genomic Viewer[12](#gcc22679-bib-0012){ref-type="ref"} (IGV, v2.3.78). Select events were validated by PCR or FISH. Star Fusion[13](#gcc22679-bib-0013){ref-type="ref"} (v0.8.0) and FusionCatcher[14](#gcc22679-bib-0014){ref-type="ref"} (v0.99.6a) were used to detect fusion transcripts in RNA‐seq data. Fusion transcript calls were contrasted with DNA SV data and visually verified on DNA level using IGV. Rearranged genes implicated in cancer were identified using the Network of Cancer Genes 5.0 (NCG 5.0) and literature search.

2.6. Detection of CNAs {#gcc22679-sec-0008}
----------------------

Copy number alterations (CNAs) were identified by Control‐FREEC[15](#gcc22679-bib-0015){ref-type="ref"} using a window size of 50 kb. The output was then subjected to a Wilcoxon rank test and a Kolmogorov‐Smirnov test to generate a list of genomic regions with statistically supported CNAs. CNA regions were visually verified using IGV and select CNA events were validated by digital droplet PCR (ddPCR). Subclonal CNA events were visually detected (coverage changes + supporting reads) using IGV. Select subclonal events were validated by Sanger sequencing.

2.7. Discovery of pathogenic SNVs {#gcc22679-sec-0009}
---------------------------------

SNVs were detected using GATK (v3.5). SNVs present in the dbSNP database were filtered out. We searched for pathogenic SNVs in 1461 genes involved in signaling pathways and cellular processes previously reported as affected in CTCL.[7](#gcc22679-bib-0007){ref-type="ref"}, [8](#gcc22679-bib-0008){ref-type="ref"}, [9](#gcc22679-bib-0009){ref-type="ref"}, [16](#gcc22679-bib-0016){ref-type="ref"}, [17](#gcc22679-bib-0017){ref-type="ref"}, [18](#gcc22679-bib-0018){ref-type="ref"}, [19](#gcc22679-bib-0019){ref-type="ref"}, [20](#gcc22679-bib-0020){ref-type="ref"}, [21](#gcc22679-bib-0021){ref-type="ref"}, [22](#gcc22679-bib-0022){ref-type="ref"} Gene lists were retrieved from the PathCards database (<http://pathcards.genecards.org/>). Only SNVs predicted to produce highly deleterious amino acid substitutions by both SIFT and PolyPhen‐2 were further investigated on ClinVar, COSMIC, and literature.

2.8. Differential expression analysis {#gcc22679-sec-0010}
-------------------------------------

EdgeR (v3.14.0) was used to normalize fragments per gene counts and determine differentially expressed (DE) genes. Each MF sample was compared individually to a control group formed by seven CD4+ T‐cell subsets (T~naïve~, T~H~1, T~H~2, T~H~17, T~reg~, T~EM~, T~CM~; five samples per subset). RNA‐seq data of T‐cell controls were generated by Ranzani et al. and downloaded from EBI (<https://www.ebi.ac.uk/>).[23](#gcc22679-bib-0023){ref-type="ref"} Testing was performed using negative binomial generalized log‐linear models. Only genes found to be commonly up‐regulated or down‐regulated (FDR \< 0.01) in all MF samples were regarded as DE genes. DE genes implicated in cancer were identified using NCG 5.0 and literature search.

2.9. Functional annotation, GSEA, and pathway analysis {#gcc22679-sec-0011}
------------------------------------------------------

Functional annotation of rearranged genes was performed using Panther[24](#gcc22679-bib-0024){ref-type="ref"} (v11.1). Gene set enrichment analysis[25](#gcc22679-bib-0025){ref-type="ref"} (GSEA, v2.2.4) was run as a preranked analysis with 1000 permutations using the hallmarks gene set from the Molecular Signatures Database (MSigDB). Normalized enrichment scores (NES) were calculated to determine expression signatures. FDR *q* values were obtained. Pathway analysis with DE genes was performed with DAVID[26](#gcc22679-bib-0026){ref-type="ref"} (v6.8) using default settings.

2.10. FISH {#gcc22679-sec-0012}
----------

FISH for CLEC16A was performed on FFPE tumor and plaque biopsies using bacterial artificial chromosome (BAC) probes. For all tumor samples except one (MF5), probe mix A (RP11‐727C18, RP11‐916G12, and RP11‐959J23; telomeric/5′) and probe mix B (RP11‐722I5, RP11‐829F21, and RP11‐936M1; centromeric/3′) were employed (Supporting Information Figure [1](#gcc22679-supitem-0001){ref-type="supplementary-material"}; Supporting Information Table [3](#gcc22679-supitem-0002){ref-type="supplementary-material"}). For sample MF5, probe mix A (telomeric/5′) and RP11‐396B14 (centromeric/3′) were used. For the two plaque samples included in this study, we used a combination of break apart and fusion FISH. Break apart probe mixes A and B were used together with patient‐specific fusion probes (MF3: RP11‐107L10, RP11‐1097K16, and RP11‐421N18; MF4: RP11‐625M5 and RP11‐1083M15) (Supporting Information Figure [1](#gcc22679-supitem-0001){ref-type="supplementary-material"}; Supporting Information Table [3](#gcc22679-supitem-0002){ref-type="supplementary-material"}). Probes were purchased from BACPAC resources at Children\'s Hospital Oakland (CHORI) and their identity confirmed by FISH on metaphase controls and Sanger sequencing. DNA was isolated from BAC clones by alkaline extraction, and labeled with haptens (digoxigenin (DIG)‐, biotin (BIO)‐ or dinitrophenyl (DNP)‐coupled dideoxynucleotides) by nick translation. FFPE tissue sections were subjected to deparaffinization in xylene, pre‐treatment in 10 mM citrate buffer, digestion in 0.4% pepsin, co‐denaturation, and hybridization with the probes. Hybridized sections were then incubated with fluorescein isothiocyanate (FITC)‐conjugated mouse anti‐DIG antibodies, Cy3‐conjugated streptavidin, and rabbit anti‐DNP antibodies; and subsequently, incubated with Alexa 488‐conjugated goat antimouse antibodies and Cy5‐conjugated goat antirabbit antibodies. Finally, sections were counterstained with 4,6 diamidino‐2‐phenylindole (DAPI). Analysis was performed by manually scoring 100 tumor cells per section.

2.11. Digital droplet PCR {#gcc22679-sec-0013}
-------------------------

Select CNAs were validated by using Bio‐Rad QX200 ddPCR system (Supporting Information Figure [2](#gcc22679-supitem-0001){ref-type="supplementary-material"}) following the manufacturer\'s guidelines. In short, 20--40 ng of genomic DNA was mixed with a frequent‐cutting restriction enzyme, ddPCR supermix, FAM‐labeled probes against the gene of interest and HEX‐labeled probes against the reference gene in a 96‐well PCR plate. Each 20 μL reaction was then transferred to a droplet generation cartridge, partitioned into nano droplets, and pipetted back to a fresh 96‐well PCR plate by using Bio‐Rad QX200 automated droplet generator. The plate containing the emulsified samples was sealed with foil and amplified on a Bio‐Rad T100 thermocycler. PCR program was the following: 95°C for 10 min, 39 cycles of 94°C for 30 s, and 60°C for 1 min, and 98°C for 10 min. The plate containing the post‐PCR nano droplets was then placed into Bio‐Rad QX200 droplet reader, which aspirates droplets and measures FAM/HEX fluorescence one droplet at a time. Copy number values were determined with Bio‐Rad Quantasoft software v1.7.4. Reported copy numbers of *HNRNPK* and *SOCS1* in samples from the validation cohort are the average of three independent measurements using different reference genes.

3. RESULTS {#gcc22679-sec-0014}
==========

3.1. Landscape of genomic rearrangements {#gcc22679-sec-0015}
----------------------------------------

The number of rearrangements ranged from 13 to 62 per patient (352 total events; mean/patient ± SD, 39 ± 18) (Figures [1](#gcc22679-fig-0001){ref-type="fig"} and [2](#gcc22679-fig-0002){ref-type="fig"}A; Supporting Information Table [4](#gcc22679-supitem-0002){ref-type="supplementary-material"}). Fifty‐two percent of events were interchromosomal (range/patient, 35%--85%) (Figure [2](#gcc22679-fig-0002){ref-type="fig"}B). Thirty‐one percent of events fused two annotated genes, while the rest joined either a gene with a nongenic region or two nongenic regions, or reshuffled sequences within a single gene. Seven percent of rearrangements resulted in fusion transcripts (mean fusions/patient, 3; range, 1--5 fusions/patient) (Figure [2](#gcc22679-fig-0002){ref-type="fig"}C; Supporting Information Table [5](#gcc22679-supitem-0002){ref-type="supplementary-material"}). We also observed chromothripsis‐like events in three patients (ie, MF1, MF6, MF9) who carry numerous complex rearrangements in chromosomes 1 and X, 6 and 10, and 1 and 5, respectively (Figures [1](#gcc22679-fig-0001){ref-type="fig"} and [2](#gcc22679-fig-0002){ref-type="fig"}D).

![Landscape of genomic rearrangements in mycosis fungoides. Circos plot depicting 352 genomic rearrangements identified in nine MF genomes by WGS. The outer ring consists of chromosome ideograms arranged circularly end to end. The inner area in the plot shows arcs that represent interchromosomal (blue) and intrachromosomal (red) rearrangements. The ring between the chromosome ideograms and the arcs contains labels indicating rearranged genes implicated in cancer \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-653-g001){#gcc22679-fig-0001}

![Distribution and functional annotation of genomic rearrangements in mycosis fungoides. A, Number of genomic rearrangements per sample. B, Distribution of inter‐ and intrachromosomal rearrangements. C, Distribution of genomic rearrangements based on the type of DNA sequences involved in the event (genic or nongenic) and the expression of fusion sequences determined through integration of WGS and RNA‐seq data. D, Circos plot illustrating chromothripsis‐like events in chromosomes 1 and X of sample MF1. The plot shows that complex rearrangements are associated with deletion of genomic regions. E, Distribution of rearranged genes according to the biological process their protein products take part in. F, Distribution of rearranged genes according to the protein class they encode (143 of 270 rearranged genes were assigned to a protein class by Panther) \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-653-g002){#gcc22679-fig-0002}

A total of 270 genes were found to be rearranged (Supporting Information Table [6](#gcc22679-supitem-0002){ref-type="supplementary-material"}), 47 of which are currently implicated in cancer (Supporting Information Table [7](#gcc22679-supitem-0002){ref-type="supplementary-material"}). This group includes genes previously associated with MF or Sézary Syndrome (SS) (ie, *CDKN2A*, *CDKN2B*, *DLEU2*, *KDM6A*, *TP53*, *TP63*, and *VAV1*)[5](#gcc22679-bib-0005){ref-type="ref"}, [19](#gcc22679-bib-0019){ref-type="ref"} and genes implicated in other hematological malignancies (eg, *ARHGAP26*, *CBFA2T3*, *CHD2*, *DOT1L*, *LCK*, *LPP*, *PBX1*, *PTPN11*, *MLLT3*, *TAF15*, *SPECC1*, *ZMYM2*) (Figure [1](#gcc22679-fig-0001){ref-type="fig"}).[27](#gcc22679-bib-0027){ref-type="ref"}, [28](#gcc22679-bib-0028){ref-type="ref"}, [29](#gcc22679-bib-0029){ref-type="ref"}, [30](#gcc22679-bib-0030){ref-type="ref"}, [31](#gcc22679-bib-0031){ref-type="ref"}, [32](#gcc22679-bib-0032){ref-type="ref"}, [33](#gcc22679-bib-0033){ref-type="ref"}, [34](#gcc22679-bib-0034){ref-type="ref"}, [35](#gcc22679-bib-0035){ref-type="ref"}, [36](#gcc22679-bib-0036){ref-type="ref"}, [37](#gcc22679-bib-0037){ref-type="ref"}, [38](#gcc22679-bib-0038){ref-type="ref"}

Functional annotation of rearranged genes reveals a diverse set of biological processes (Figure [2](#gcc22679-fig-0002){ref-type="fig"}E; Supporting Information Table [8](#gcc22679-supitem-0002){ref-type="supplementary-material"}), being cell physiology (*n* ~genes~ = 113) and metabolism (*n* ~genes~ = 92) the highest ranking categories. Breakdown of these two categories shows that cell communication (*n* ~genes~ = 34) and cell cycle (*n* ~genes~ = 16) are the most affected physiological processes while nucleic acid metabolism (*n* ~genes~ = 48, esp. transcription) leads the group of impacted biochemical processes (Supporting Information Table [8](#gcc22679-supitem-0002){ref-type="supplementary-material"}).

In support of the postulated deleterious effects of genomic rearrangements on normal cellular functions, at least 100 rearranged genes (127/270 genes could not be assigned to a protein class by Panther) encode proteins with relevant roles in signal transduction (eg, ligands, receptors, enzyme modulators) and transcriptional regulation (eg, transcription factors, chromatin regulators) (Figure [2](#gcc22679-fig-0002){ref-type="fig"}F; Supporting Information Table [9](#gcc22679-supitem-0002){ref-type="supplementary-material"}). Nonetheless, rearranged genes do not group into a single or a few signaling pathways, but take part in numerous different pathways/processes.

We found nine recurrently rearranged genes, *ARHGAP26* (two of nine patients), *ATXN1* (two of nine), *CLEC16A* (four of nine), *ELF1* (two of nine), *EYS* (two of nine), *RBPJ* (two of nine), *RPS6KA3* (two of nine), *SLC24A2* (two of nine), and *SSH2* (two of nine) in our sequenced cohort. However, in all cases fusion partners differ between patients and the resulting chimeric sequences are expressed only in single patients (five of nine rearranged genes) or not expressed (four of nine). Interestingly, 50% of recurrent CNAs containing cancer genes are associated with inter‐ or intrachromosomal rearrangements. For instance, *ARID1A*, *CDKN2A/B*, *PTPRC*, *SOCS1*, and *STK11* are deleted as a consequence of chromosomal rearrangements in two or more patients. This fact, together with the small percentage of expressed gene fusions, suggests that in MF, rearrangements more often mediate inactivation of tumor suppressors, rather than generate oncogenic fusions.

3.2. Aneuploidies and CNAs {#gcc22679-sec-0016}
--------------------------

Large‐scale numerical abnormalities (\>3 Mb) included trisomy 4 (one of nine patients), 7 (two of nine) and 18 (two of nine), as well as deletions within 9q (four of nine patients), 10q (two of nine) and 16q (three of nine), and gains within 3q (three of nine patients), 5p (three of nine), 7q (two of nine), 8q (two of nine) and 17q (four of nine) (Figures [3](#gcc22679-fig-0003){ref-type="fig"} and [4](#gcc22679-fig-0004){ref-type="fig"}).

![Overview of CNAs in mycosis fungoides. Human chromosome ideograms showing regions of gain and loss identified by WGS in nine MF genomes. Red bars to the left of each chromosome represent regions of gain while blue bars to the right of each chromosome represent regions of loss \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-653-g003){#gcc22679-fig-0003}

![Distribution of recurrent CNAs and pathogenic SNVs in mycosis fungoides. Upper panel, broad CNAs (\>3 Mb); middle panel, focal MCRs (≤3 Mb) shared by CNAs. *Bona fide* cancer genes contained within each focal MCR are indicated; bottom panel, pathogenic SNVs. Only SNVs for which functional validation has been reported in literature are shown \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-653-g004){#gcc22679-fig-0004}

We identified 18 focal (≤3 Mb) minimal common regions (MCRs) shared by CNAs, with 15/18 MCRs containing cancer genes (Figures [3](#gcc22679-fig-0003){ref-type="fig"} and [4](#gcc22679-fig-0004){ref-type="fig"}; Supporting Information Table [10](#gcc22679-supitem-0002){ref-type="supplementary-material"}). These focal MCRs affect genes primarily involved in cell cycle control, chromatin regulation, the JAK‐STAT pathway, and the PI‐3‐K pathway.

The most frequent focal MCR was 9p21.3 deletion, found in seven of nine patients. This region encloses exon 2 and 3 of *CDKN2A*. We found deletions at 16p13.13 and 9q21.32 in five of nine patients, which include JAK‐STAT pathway regulator *SOCS1* and *TP53*‐dependent p21 co‐activator *HNRNPK*, respectively.

Deletions at 1q31.3 and 13q14.3 were observed in four of nine patients. The former involves JAK‐STAT inhibitor *PTPRC* while the latter contains the *DLEU2/Mir‐15a/16‐1* locus, which is frequently deleted in chronic lymphocytic leukemia (CLL).[39](#gcc22679-bib-0039){ref-type="ref"}

Additionally, three of nine patients had deletions at 1p36.11, 9q21.31, 10q23.31, 13q14.11, 19p13.3, and 20q13.13, which include tumor suppressors *ARID1A*, *TLE4*, *PTEN*, *FOXO1*, *STK11* (alongside *TCF3*) and *PTPN1*, respectively. Lastly, two of nine patients presented deletions at 5q15‐21.1, 6p22.3, and 16q24.3 which involve (putative) tumor suppressors *CHD1*, *JARID2*, and *CBFA2T3*, respectively.

In contrast, focal MCRs within gain areas were rare (*n =* 3), with gain at 8q24.21 (involving *MYC*) found in two of nine patients, being the only event containing a cancer gene.

3.3. Pathogenic SNVs {#gcc22679-sec-0017}
--------------------

Prior studies showed that recurrent pathogenic SNVs in MF are rare.[7](#gcc22679-bib-0007){ref-type="ref"}, [8](#gcc22679-bib-0008){ref-type="ref"}, [9](#gcc22679-bib-0009){ref-type="ref"}, [19](#gcc22679-bib-0019){ref-type="ref"} Nevertheless, we looked for pathogenic SNVs in exonic sequences of genes involved in the JAK--STAT pathway, the MAPK pathway, the NF‐κB pathway, the PI‐3‐K pathway, the T‐cell receptor (TCR) pathway, cell cycle control, chromatin organization, and genes that are presumed drivers[19](#gcc22679-bib-0019){ref-type="ref"} in CTCL (Supporting Information Table [11](#gcc22679-supitem-0002){ref-type="supplementary-material"}).

Recurrent SNVs were found in two genes, *FGFR4* (p.G388R,[40](#gcc22679-bib-0040){ref-type="ref"} three of nine patients; expressed: 1/3) and *JAK3* (p.A573V,[41](#gcc22679-bib-0041){ref-type="ref"} two of nine patients), both of which are known gain‐of‐function mutations. The remaining SNVs predicted as pathogenic occur in single patients only. These include gain‐of‐function SNVs in *BRAF* (p.G466E[42](#gcc22679-bib-0042){ref-type="ref"}), *JAK3* (p.V722I[43](#gcc22679-bib-0043){ref-type="ref"}), *KRAS* (p.G13C[44](#gcc22679-bib-0044){ref-type="ref"}), *MYD88* (p.L273P[45](#gcc22679-bib-0045){ref-type="ref"}), and *STAT3* (p.Y640F[46](#gcc22679-bib-0046){ref-type="ref"}), which have been reported either in CTCL or other malignancies and functionally validated elsewhere (Figure [4](#gcc22679-fig-0004){ref-type="fig"}; Supporting Information Figure [3](#gcc22679-supitem-0001){ref-type="supplementary-material"}); also, SNVs in *CHEK2* (p.I200T[47](#gcc22679-bib-0047){ref-type="ref"}) and *MITF* (p.E419K[48](#gcc22679-bib-0048){ref-type="ref"}), which are germline risk factors for breast cancer and melanoma, respectively (Figure [4](#gcc22679-fig-0004){ref-type="fig"}); and 47 other patient‐specific SNVs (predicted as highly deleterious by PolyPhen‐2 and SIFT) (Supporting Information Table [12](#gcc22679-supitem-0002){ref-type="supplementary-material"}) located in genes with relevant roles in the aforesaid pathways. Importantly, pathogenic SNVs in genes from the JAK‐STAT and MAPK pathway are not mutually exclusive.

3.4. Differentially expressed genes and fusion transcripts {#gcc22679-sec-0018}
----------------------------------------------------------

We identified differentially expressed (DE) genes by comparing expression in our MF cohort with expression in normal CD4+ T cells. Since the cell of origin of MF remains unidentified, transcriptome analysis was performed using a control group formed by several CD4+ T‐cell subsets (see Materials and Methods) with the aim of detecting aberrant expression patterns that are absent in a range of normal CD4+ phenotypes. A total of 733 genes (450 up‐regulated, 283 down‐regulated, FDR \<0.01) were found to be differentially expressed (Figure [5](#gcc22679-fig-0005){ref-type="fig"}A, Supporting Information Table [13](#gcc22679-supitem-0002){ref-type="supplementary-material"}). We next used NCG 5.0 to pinpoint DE genes implicated in cancer. Eighty‐one cancer genes (51 up‐regulated, 30 down‐regulated) were identified (Supporting Information Table [14](#gcc22679-supitem-0002){ref-type="supplementary-material"}). Up‐regulated genes include oncogenes *MALAT1*, *MECOM*, *PBX1*, *TTK*, and *WWTR1*, whereas down‐regulated genes include tumor suppressors *BRD7*, *CDKN1B*, *CYLD*, *HNRNPK*, *TSC1*, and *XPA*. The expression profile also comprises up‐regulation of developmental genes *GLI3*, *JAG1*, and *NOTCH3*, and down‐regulation of transcriptional repressor *FOXP1* and cell proliferation inhibitors *GPS2* and *RHOH* (Figure [5](#gcc22679-fig-0005){ref-type="fig"}B--D).

![RNA‐seq identifies differentially expressed cancer genes and deregulated signaling pathways in mycosis fungoides. A, Heat map of differentially expressed (DE) genes (FDR \< 0.01) in MF when compared to CD4+ T cells. Of 733 DE genes, 450 were commonly up‐regulated and 283 were commonly down‐regulated. B, Oncogenes and tumor suppressors with roles in cell cycle control and development are among the group of DE genes. C and D, *HNRNPK* and *MECOM*, whose deregulation (down‐ and up‐, respectively) are reported to enhance the JAK‐STAT pathway, are differentially expressed in MF (*HNRNPK*: −2.5‐fold average, \*\*\**P* \< 1 × 10^−4^; *MECOM*: 31‐fold average, \*\*\**P* \< 1 × 10^−4^, Mann‐Whitney test). E, Gene set enrichment analysis. Select GSEA plots showing up‐regulation of STAT3 signaling (upper left), KRAS signaling (upper right), Hedgehog signaling (lower left) and Notch signaling (lower right) in MF compared to CD4+ T cells (see Supporting Information Table [15](#gcc22679-supitem-0002){ref-type="supplementary-material"} for a complete list of GSEA signatures). NES, normalized enrichment score; FDR *q*‐value, false discovery rate *q*‐value. F and G, Pathway analysis by DAVID reveals up‐regulation of the PI‐3‐K/Akt pathway, the cell cycle and cancer signatures, and down‐regulation of ribosome, spliceosome and mRNA surveillance (see Supporting Information Table [16](#gcc22679-supitem-0002){ref-type="supplementary-material"} for a complete list of enriched terms/processes) \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-653-g005){#gcc22679-fig-0005}

We detected 24 patient‐specific fusion transcripts (Table [1](#gcc22679-tbl-0001){ref-type="table"}), including 6 (ie, *ATXN1‐TP63*, *CCR7‐DOT1L*, *KDM6A‐IL1RAPL1*, *LMF1‐TAF15*, *TP53‐GPR3*, and *YTHDF3‐LIFR*) that contain genes implicated in cancer. To our knowledge, with the exception of *ATXN1‐TP63,* [49](#gcc22679-bib-0049){ref-type="ref"} all these chimeric transcripts are reported for the first time.

###### 

Fusion transcripts detected by RNA‐seq in tumor‐stage MF

  Sample   Fusion transcript   Breakpoints (DNA)                  Breakpoint type   Event class   WGS confirmed
  -------- ------------------- ---------------------------------- ----------------- ------------- ---------------
  MF1      *KDM6A--IL1RAPL1*   chrX:44746566--chrX:29451290       Genic--genic      ITX           Yes
  MF1      *CHIC1--RP2*        chrX:72844450--chrX:46680435       Genic--nongenic   ITX           Yes
  MF3      *ANKRD13A--CUL9*    chr12:110448655--chr6:43160142     Genic--genic      CTX           Yes
  MF3      *CLEC16A--SCARB1*   chr16:11067010--chr12:125350896    Genic--nongenic   CTX           Yes
  MF3      *SSH2--GRAP2*       chr17:28059210--chr22:40314573     Genic--genic      CTX           Yes
  MF3      *LMF1--TAF15*       chr16:986148--chr17:34145925       Genic--genic      CTX           Yes
  MF3      *ATXN1--TP63*       chr6:16307814--chr3:189470345      Genic--genic      CTX           Yes
  MF4      *CCR7--DOT1L*       chr17:38718403--chr19:2181252      Genic--genic      CTX           Yes
  MF5      *PHACTR4--EPB41*    chr1:28755797--chr1:29246304       Genic--genic      iDel          Yes
  MF5      *ADAM12--MMRN2*     chr10:127935628--chr10:88698606    Genic--genic      iDel          Yes
  MF5      *TRAPPC10--TRPM2*   chr21:45487448--chr21:45795335     Genic--genic      iDel          Yes
  MF5      *ARHGAP26--TENM2*   chr5:142272242--chr5:167448836     Genic--genic      ITX           Yes
  MF6      *ANK3--RNLS*        chr10:62168031--chr10:90101461     Genic--genic      ITX           Yes
  MF6      *ELF1--SATB2*       chr13:41540637--chr2:200369768     Genic--nongenic   CTX           Yes
  MF7      *TP53--GPR3*        chr17:7579754--chr1:27718138       Genic--nongenic   CTX           Yes
  MF7      *CLPP--NR3C1*       chr19:6365544--chr5:142800539      Genic--genic      CTX           Yes
  MF7      *SARNP--WRAP53*     chr12:56161974--chr17:7593927      Genic--genic      CTX           Yes
  MF8      *SETD5--RNF19A*     chr3:9497374--chr8:101391443       Genic--nongenic   CTX           Yes
  MF8      *SUDS3--TMEM132B*   chr12:118847216--chr12:125987360   Genic--genic      ITX           Yes
  MF8      *AACS--STAB2*       chr12:125625503--chr12:104094623   Genic--genic      ITX           Yes
  MF8      *RPUSD3--RNF19A*    chr3:9882804--chr8:101303862       Genic--genic      CTX           Yes
  MF8      *YTHDF3--LIFR*      chr8:64081882--chr5:38586949       Genic--genic      CTX           Yes
  MF9      *DPM1--UBE2V1*      chr20:49574368--chr20:48703893     Genic--genic      iDel          Yes
  MF9      *KCNAB2--ESPN*      chr1:6071941--chr1:6493075         Genic--genic      iDel          Yes

Abbreviations: CTX, interchromosomal translocation. ITX, intrachromosomal translocation. iDel, interstitial deletion.

3.5. Deregulated signaling pathways {#gcc22679-sec-0019}
-----------------------------------

To look for evidence of deregulated pathways in MF, we performed GSEA using annotated gene sets from MSigDB to look for expression signatures. The analysis revealed up‐regulation of IL6‐JAK‐STAT3 signaling (NES = 1.75, FDR *q‐*value = 2.62 × 10^−4^), KRAS signaling (NES = 1.65, FDR *q‐*value = 1.8 × 10^−3^), Hedgehog signaling (NES = 1.66, FDR *q‐*value = 1.8 × 10^−3^), and Notch signaling (NES = 1.55, FDR *q‐*value = 0.01) (Figure [4](#gcc22679-fig-0004){ref-type="fig"}E; Supporting Information Table [15](#gcc22679-supitem-0002){ref-type="supplementary-material"}).

In addition, we performed DAVID pathway analysis with up‐ and down‐regulated genes separately. Cellular processes associated with integrin‐mediated signaling (ie, ECM‐receptor interaction, focal adhesion), PI‐3‐K/Akt signaling (*P* = 4.6 × 10^−10^), cancer signatures (ie, viral carcinogenesis, small cell lung cancer) and cell cycle (*P* = 1.1 × 10^−5^) are prominent up‐regulated profiles in MF (Figure [5](#gcc22679-fig-0005){ref-type="fig"}F; Supporting Information Table [16](#gcc22679-supitem-0002){ref-type="supplementary-material"}). Down‐regulated profiles include ribosome (*P* = 1.0 × 10^−36^) and spliceosome (*P* = 8.7 × 10^−9^) activity, and mRNA surveillance (*P* = 4.1 × 10^−4^) (Figure [5](#gcc22679-fig-0005){ref-type="fig"}G; Supporting Information Table [16](#gcc22679-supitem-0002){ref-type="supplementary-material"}).

3.6. *SOCS1* and *HNRNPK* are recurrently deleted {#gcc22679-sec-0020}
-------------------------------------------------

From all structural alterations revealed by our analysis, deletion of *HNRNPK* and *SOCS1* stand out because of their novelty and recurrence. Notably, apart from being deleted in five of nine sequenced patients, *HNRNPK* is down‐regulated in eight of eight transcriptomes (2.5‐fold average, *P* \< 1 × 10^−4^) (Figures [5](#gcc22679-fig-0005){ref-type="fig"}C and [7](#gcc22679-fig-0007){ref-type="fig"}A) whereas *SOCS1* deletions are invariably focal (≤3 Mb) in five of five affected patients (MCR: 305 kb, three genes) (Figures [6](#gcc22679-fig-0006){ref-type="fig"} and [7](#gcc22679-fig-0007){ref-type="fig"}B; Supporting Information Figure [4](#gcc22679-supitem-0001){ref-type="supplementary-material"}). Consequently, we evaluated copy number of *HNRNPK* and *SOCS1* in 18 additional tumor biopsies by ddPCR. In this extension cohort we found *HNRNPK* deletion in five patients and *SOCS1* deletion in four patients (Figure [7](#gcc22679-fig-0007){ref-type="fig"}C,D). Taking together the sequenced and extension cohorts, *HNRNPK* was deleted in 10 of 27 (37%) patients and *SOCS1* in 9 of 27 (33%) patients.

![Genomic rearrangements at 16q13.13 are associated with focal *SOCS1* deletions in mycosis fungoides. (I) Circos plots displaying genomic rearrangements at 16q13.13. (II) Magnified views of deletions at 16q13.13 resulting from structural alterations. Genomic rearrangements at 16q13.13 validated by (III) Sanger sequencing and (IV) break apart FISH in (A) MF3, (B) MF4, and (C) MF5. Del, deletion. CTX, interchromosomal translocation. Scale bar, 10 μm \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-653-g006){#gcc22679-fig-0006}

![*HNRNPK* and *SOCS1* are recurrently deleted in mycosis fungoides. Deletion of (A) *HNRNPK* and (B) *SOCS1* in sequenced tumor samples was confirmed by ddPCR. Deletion of (C) *HNRNPK* and (D) *SOCS1* was also identified in samples from the extension cohort by ddPCR. E, The translocation responsible for *SOCS1* deletion in sample MF4 was found in (early‐stage) plaque tissue by FISH. Ctrl, CD4+ T cells. Scale bar, 10 μm \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-57-653-g007){#gcc22679-fig-0007}

3.7. Deletion of *SOCS1* can be found at early stage {#gcc22679-sec-0021}
----------------------------------------------------

We seized upon the fact that *SOCS1* deletions mostly result from translocations in our sequenced cohort to investigate their occurrence at early stage. We used a combination of break‐apart and fusion FISH to search for *SOCS1*‐deleting translocations in available plaque‐stage tissue from two sequenced patients (MF3 and MF4) with confirmed *SOCS1*‐deleting translocations in tumor‐stage tissue (Figure [6](#gcc22679-fig-0006){ref-type="fig"}). Plaque biopsies from patients MF3 and MF4 were procured, respectively, 3 years and 8 months prior to tumor development. We found that patient MF4 bears the translocation at plaque‐stage too (Figure [7](#gcc22679-fig-0007){ref-type="fig"}E), suggesting that *SOCS1* deletion is an early event in this individual.

4. DISCUSSION {#gcc22679-sec-0022}
=============

This study represents the first integrated analysis (DNA/RNA) of genomic rearrangements in MF. The analysis reveals that MF displays a complex and heterogeneous landscape of inter‐ and intrachromosomal rearrangements. We observed, among others, translocations leading to deletion of *ARID1A*, *CDKN2A/B*, *PTPRC*, *SOCS1*, and *STK11*. This suggests that rearrangements mediate the deletion of tumor suppressors involved in pathways that are commonly deregulated in MF patients. We detected 270 rearranged genes, of which at least 100 play diverse roles in signal transduction and transcriptional regulation, and 47 are currently implicated in neoplasms. Our analysis identified 24 fusion transcripts, including 6 containing *bona fide* cancer genes, which though not recurrent, may contribute to MF development in individual cases.

All potentially deleterious SNVs we observed are patient‐specific, with the exception of *FGFR4* (p.G388R) and *JAK3* (p.A573V). Still, pathogenic SNVs may play relevant roles in signaling deregulation in some individuals. Importantly, we observed numerous SNVs in two genes reported as putative drivers in CTCL (ie, *KMT2C, NCOR1*), which albeit predicted as highly deleterious, were not found to be expressed in the RNA‐seq data. This highlights the importance of integrating DNA and RNA analyses to evaluate mutational data.

Although phenotypic resemblance between MF cells and several CD4+ T‐cell subsets (ie, T~H~2,[50](#gcc22679-bib-0050){ref-type="ref"} T~H~17,[51](#gcc22679-bib-0051){ref-type="ref"} T~RM~ [52](#gcc22679-bib-0052){ref-type="ref"}) has been documented in previous years, there is no definitive proof of any of these potential origins. Despite the cell of origin of MF remains undetermined, aberrant expression detected in our MF cohort using a "pan"‐ CD4+ control group matches earlier observations made by other groups. For instance, overactivation of JAK‐STAT[53](#gcc22679-bib-0053){ref-type="ref"}, [54](#gcc22679-bib-0054){ref-type="ref"} and NOTCH[55](#gcc22679-bib-0055){ref-type="ref"} signaling, and mutations that enhance RAS‐mediated signaling[56](#gcc22679-bib-0056){ref-type="ref"} have been previously described in MF. Yet, our transcriptome data should be interpreted with caution as further confirmation is required once the exact CD4+ T‐cell subset giving rise to MF is identified.

Interestingly, transcriptome analysis reveals a subset of DE cancer genes that play roles in cell cycle regulation and development. Tumor suppressors *BRD7*, *CDKN1B*, *GPS2*, and *HNRNPK*, which are down‐regulated in MF, are known to prompt cell cycle arrest at G1/S.[57](#gcc22679-bib-0057){ref-type="ref"}, [58](#gcc22679-bib-0058){ref-type="ref"}, [59](#gcc22679-bib-0059){ref-type="ref"} *TSC1*, down‐regulated too, sustains quiescence in naïve T cells and its abrogation results in rapid cycling behavior.[60](#gcc22679-bib-0060){ref-type="ref"} *PBX1*, a direct transcriptional repressor of *CDKN2B*, is consistently up‐regulated in MF.[61](#gcc22679-bib-0061){ref-type="ref"} Additionally, up‐regulation of mitotic checkpoint kinase *TTK* might contribute to genomic instability in MF, since its expression has been shown to prevent aneuploidy‐induced cell death.[62](#gcc22679-bib-0062){ref-type="ref"}

On the other hand, up‐regulation of developmental genes *GLI3*, *JAG1*, and *NOTCH3* might contribute to boost cell proliferation. Notably, NOTCH3 overactivation has been shown to induce an auto‐sustaining JAG1 expression loop in T‐cell acute lymphoblastic leukemia (T‐ALL), which in turn, enhances expression of Notch target genes responsible for the progression of the disease.[63](#gcc22679-bib-0063){ref-type="ref"}

Moreover, transcriptome analysis also shows that processes related to transcription (ie, spliceosome activity, mRNA surveillance) are flawed in MF, which might be linked to the considerable number of transcription‐related genes affected by genomic rearrangements. Taken together, the structural and expression analyses show that the cell cycle, the JAK‐STAT pathway, the PI‐3‐K pathway, and developmental pathways are deregulated in MF.

We report for the first time recurrent deletion of *HNRNPK* and *SOCS1* not only in MF, but any CTCL. Furthermore, we found evidence that *SOCS1* deletion is an early event in one of two patients with available plaque‐stage material by FISH. Importantly, while the incidence of deletion of both genes in the extension cohort was lower compared to the sequenced cohort, this difference was not statistically significant (*P* \> .05, Fisher\'s exact test). Moreover, we can rule out the existence of clinical differences between the tumors from the two cohorts.

hnRNP‐K is a nuclear ribonucleoprotein implicated in leukemogenesis of acute myeloid leukemia (AML).[59](#gcc22679-bib-0059){ref-type="ref"} Interestingly, studies have shown that haploinsufficiency of *HNRNPK* not only down‐regulates p21, but also up‐regulates STAT3 signaling and give rise to B‐ and T‐cell lymphomas in a mouse model.[59](#gcc22679-bib-0059){ref-type="ref"} On the other hand, *SOCS1*, which is silenced in several cancers including multiple myeloma (MM),[64](#gcc22679-bib-0064){ref-type="ref"} inhibits JAK‐STAT signaling by suppressing the tyrosine kinase activity of JAK proteins.[65](#gcc22679-bib-0065){ref-type="ref"}

A noteworthy fact is that miR‐155, which is often up‐regulated in MF,[6](#gcc22679-bib-0006){ref-type="ref"} has been found to target *SOCS1* in breast cancer and laryngeal carcinoma, leading to constitutive STAT3 activation in both cancers.[66](#gcc22679-bib-0066){ref-type="ref"}, [67](#gcc22679-bib-0067){ref-type="ref"} We observed that two of three patients without *SOCS1* deletions express much higher levels (sevenfold average) of miR‐155 precursor *MIR155HG* than patients with *SOCS1* deletions (Supporting Information Figure [5](#gcc22679-supitem-0001){ref-type="supplementary-material"}), which suggests that miR‐155 levels rise to inhibit *SOCS1* in patients with functional copies of the gene. Moreover, *SOCS1* might be suppressed in MF in one additional way. *MECOM*, which is consistently up‐regulated in our sequenced cohort, has been found to inhibit the expression of several regulators of the JAK‐STAT pathway in AML, particularly *SOCS1*.[68](#gcc22679-bib-0068){ref-type="ref"} This evidence suggests that deregulation of STAT3 signaling via inactivation of *HNRNPK* and *SOCS1* might be important in the pathogenesis of MF. Future studies with cells and animal models will be essential to functionally confirm the association between these tumor suppressors, their regulators, and STAT3 signaling in MF. In this scenario, targeting miR‐155 and/or *MECOM* to treat patients with functional *SOCS1* alleles constitute potential novel therapeutic strategies.

Overall, the findings in this study reveal that genomic rearrangements and CNAs play relevant roles in the pathogenetics of MF and position *HRNRPK* and *SOCS1* as putative drivers of MF development.
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**Supplementary Figure 1 Genomic location of BAC probes used in FISH experiments.** (A) Break‐apart BAC probes for the validation of DNA breaks at 16q13.13 in tumor‐stage MF. (B) Fusion BAC probes for the detection of t(12;16) in plaque‐stage tissue of sample MF3. (C) Fusion BAC probes for the detection of t(16;18) in plaque‐stage tissue of sample MF4. See Supplementary Table 3 for exact genomic positions of BAC probes used in this study.

**Supplementary Figure 2. Validation of select CNAs by ddPCR.** (A) Deletion of tumor suppressors (I) *PTEN* and (II) *TLE4* in tumor‐stage MF were confirmed by ddPCR. (B) Gain of oncogenes (I) *MYC* and (II) *TERT* in tumor‐stage MF were confirmed by ddPCR. Ctrl, CD4+ T cells.

**Supplementary Figure 3. Sanger sequencing validation of select SNVs.** (A) Sanger chromatograms of tumor‐stage MF DNA showing select point mutations with known pathogenic effects (ie, gain‐of‐function, susceptibility to disease). (B) Sanger chromatograms of tumor‐stage MF DNA showing select point mutations with predicted deleterious effects on protein function. Genomic coordinates according to reference genome Hg19.

**Supplementary Figure 4. Validation of genomic alterations at 16q13.13 associated with focal *SOCS1* deletions in mycosis fungoides.** (A) Deletion event at 16q13.13 in MF7 confirmed by Sanger sequencing. (B) (I) Circos plot displaying a genomic rearrangement at 16q13.13 in MF8. (II) Magnified view of deletions (Del A and Del B) at 16q13.13 resulting from structural alterations in MF8. (III) Genomic events (Del A and Del B) at 16q13.13 validated by Sanger sequencing in MF8. Del, deletion. CTX, interchromosomal translocation.

**Supplementary Figure 5. *MIR155HG* expression in tumor‐stage MF**. Two out of three MF samples with intact copies of *SOCS1* (*SOCS1 +)* express higher levels (7‐fold average) of transcript *MIR155HG* compared to MF samples with *SOCS1* deletions (*SOCS1* ‐). *MIR155HG* hosts miR‐155, a known inhibitor of *SOCS1*.

###### 

Click here for additional data file.

###### 

**Supplementary Table** 1 Clinical information of samples used in the study

**Supplementary Table** 2 Mapping and Coverage metrics of samples subjected to WGS

**Supplementary Table** 3 BAC probes used in FISH experiments

**Supplementary Table** 4 Genomic rearragements detected by WGS

**Supplementary Table** 5 Fusion transcripts detected by RNA‐seq

**Supplementary Table** 6 Genes affected by genomic rearrangements

**Supplementary Table** 7 Genes affected by genomic rearrangements and implicated in cancer

**Supplementary Table** 8 Functional annotation (Biological process) of genes affected by genomic rearrangements

**Supplementary Table** 9 Functional annotation (Protein Class) of genes affected by genomic rearrangements

**Supplementary Table** 10 Minimal common regions (MCRs) between copy number alterations

**Supplementary Table** 11 Genes screened for deleterious SNVs

**Supplementary Table** 12 SNVs predicted as deleterious by Polyphen‐2 & SIFT

**Supplementary Table** 13 Differentially expressed genes in MF when compared to CD4+ T cells

**Supplementary Table** 14 Differentially expressed genes implicated in cancer

**Supplementary Table** 15 GSEA: Expression signatures enriched in MF when compared to CD4+ T cells

**Supplementary Table** 16 Up‐regulated and down‐regulated processes/pathways in MF

###### 

Click here for additional data file.
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